Kalaris Therapeutics (KLRS) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kalaris Therapeutics (KLRS) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 49.0% versus a loss of 83.3%. Over five years, MREO leads with a -83.9% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($56.2 million vs $55.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | MREO |
|---|---|---|
| Share price | $2.36 | $0.3499 |
| Market cap | $56.18M | $55.88M |
| 1-day change | -5.60% | -6.74% |
| YTD return | -72.04% | -16.09% |
| 1-year return | -48.97% | -83.34% |
| 5-year return | -99.54% | -83.95% |
| EPS (TTM) | $-2.02 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.88 | $2.37 |
| 52-week low | $2.35 | $0.20 |
| Distance from 52-week high | -80.13% | -85.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +692.80% | +460.16% |
| Average volume | 252.88K | 4.08M |
| Shares outstanding | 23.80M | 159.69M |
| Employees | 20 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KLRS has outperformed MREO by 34.4 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
KLRS vs MREO FAQ
Which is bigger, Kalaris Therapeutics or Mereo BioPharma Group?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $56.18M compared with $55.88M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, KLRS or MREO?
KLRS returned -48.97% over the past 12 months, compared with -83.34% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and Mereo BioPharma Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Kalaris Therapeutics and Biotechnology: Pharmaceutical Preparations for Mereo BioPharma Group.